Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog - TheStreet

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
9/27/16 7:00AM
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
9/27/16 6:27AM
Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.
9/26/16 4:32PM
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
9/26/16 11:41AM
Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.
9/24/16 3:00PM
An Alzheimer's drug under development by Danish pharma Lundbeck failed a pivotal phase III study and Axovant suffered collateral damage.
9/22/16 12:32PM
When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.
9/21/16 6:30AM
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
9/20/16 6:55AM
Sarepta, its shareholders, biotech investors, and Duchenne patients and their families have been waiting years for today's news.
9/19/16 2:43PM
Sarepta's largest shareholder talks about the company's future following FDA approval of its Duchenne muscular dystrophy drug.
9/19/16 12:54PM
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
9/16/16 11:47AM
Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.
9/15/16 11:17AM
The departure of an important eteplirsen critic from the FDA could be a sign that the internal agency debate over Sarepta's drug is coming to an end.
9/14/16 12:55PM
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?
9/12/16 8:35AM
Important clinical trial results in Alzheimer's, cancer and Crohn's disease and a big FDA decision for Sarepta are expected before the end of the year.
9/9/16 9:14AM
Bluebird Bio removed a significant concern investors had about its gene therapy manufacturing process, sending shares higher Thursday.
9/8/16 10:36AM
Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.
9/7/16 8:35AM
Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
9/7/16 8:10AM
CEO Brent Saunders said Allergan will act differently, pledging to limit price increases on drugs the company sells as part of a 'commitment to innovation, access and responsible pricing ideals.'
9/6/16 9:20AM
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
9/6/16 8:50AM
GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.
9/5/16 7:18PM
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
8/31/16 7:27AM
The 18% response rate for fostamatinib in the Rigel phase III study was on the lower end of investor expectations.
8/30/16 7:44AM
The drugmaker says it will launch the product in 'several weeks' at a list price of $300 per two-park carton.
8/29/16 12:04PM